Literature DB >> 33493634

Extranodal NK/T cell lymphoma, nasal type: an updated overview.

Celeste Sanchez-Romero1, Ronell Bologna-Molina2, Oslei Paes de Almeida3, Alan Roger Santos-Silva3, Ana Carolina Prado Ribeiro4, Thaís Bianca Brandão4, Román Carlos5.   

Abstract

Extranodal NK/T-cell lymphoma, nasal type (ENKTCL-NT) is an aggressive malignancy associated with Epstein-Barr virus infection, with a geographic and racial predilection for some Asian and Latin American countries. ENKTCL-NT manifests as a necrotic process affecting nasal or upper aerodigestive structures and, rarely, extranasal sites such as skin, and the gastrointestinal tract. ENKTCL-NT was characterized by its poor prognosis irrespective of clinical stage and therapy. However, during the last two decades, advances in its clinicopathologic, genetic and molecular characterization have been achieved, as have changes in the chemotherapy regimens that, in combination with radiotherapy, are significantly improving the survival of these patients, especially in initial stages. For these reasons, we present an overview of the historical background of ENKTCL-NT along with an updated review of its potential etiological factors, clinicopathologic and molecular features, as well as its prognostic models, current treatment protocols, and future directions on potential promising therapeutic approaches.
Copyright © 2021. Published by Elsevier B.V.

Entities:  

Keywords:  Chemotherapy; Extranodal NK-T-Cell Lymphoma, Nasal Type; Herpesvirus 4, Human; Immunophenotype; Immunotherapy; Nasal lymphoma; Pathogenesis; Radiotherapy

Year:  2021        PMID: 33493634     DOI: 10.1016/j.critrevonc.2021.103237

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  7 in total

1.  Nonhealing Ulcers with Rimming of the Adipose Tissues.

Authors:  Kittipong Wantavornprasert; Thiti Asawapanumas; Pravit Asawanonda
Journal:  Case Rep Dermatol       Date:  2022-07-05

2.  Comprehensive Analysis and Summary of the Value of Immunophenotypes of Mature NK Cell Tumors for Differential Diagnosis, Treatment, and Prognosis.

Authors:  Qiyao Pu; Xueyan Cao; Yuke Liu; Dongyao Yan; Ran Tan; Jiwei Li; Baohong Yue
Journal:  Front Immunol       Date:  2022-06-24       Impact factor: 8.786

Review 3.  EBV-Driven Lymphoproliferative Disorders and Lymphomas of the Gastrointestinal Tract: A Spectrum of Entities with a Common Denominator (Part 3).

Authors:  Magda Zanelli; Francesca Sanguedolce; Andrea Palicelli; Maurizio Zizzo; Giovanni Martino; Cecilia Caprera; Valentina Fragliasso; Alessandra Soriano; Fabrizio Gozzi; Luca Cimino; Francesco Masia; Marina Moretti; Moira Foroni; Loredana De Marco; David Pellegrini; Hendrik De Raeve; Stefano Ricci; Ione Tamagnini; Alessandro Tafuni; Alberto Cavazza; Francesco Merli; Stefano A Pileri; Stefano Ascani
Journal:  Cancers (Basel)       Date:  2021-11-30       Impact factor: 6.639

4.  Combination of Anti-PD-1 Antibody, Anlotinib and Pegaspargase "Sandwich" With Radiotherapy in Localized Natural Killer/T Cell Lymphoma.

Authors:  Peng Sun; Yu Wang; Hang Yang; Cui Chen; Man Nie; Xiao-Qing Sun; Xiao-Hua He; Kang-Ming Huang; Jia-Jia Huang; Zhi-Ming Li
Journal:  Front Immunol       Date:  2022-02-14       Impact factor: 7.561

5.  First observation of intraocular extranodal natural killer/T-cell lymphoma secondary to a retroperitoneal tumour: a case report and comparative review.

Authors:  Binyao Chen; Shizhao Yang; Wenru Su
Journal:  BMC Ophthalmol       Date:  2022-03-26       Impact factor: 2.209

6.  Evaluation of different staging systems and prognostic analysis of nasal-type extranodal NK/T-cell lymphoma based on consistent LVDP chemotherapy regimen.

Authors:  Wanchun Wu; Kexin Ren; Na Li; Qian Luo; Caigang Xu; Liqun Zou
Journal:  Transl Oncol       Date:  2022-04-27       Impact factor: 4.803

Review 7.  The Pathologic and Genetic Characteristics of Extranodal NK/T-Cell Lymphoma.

Authors:  Hyunsung Kim; Young Hyeh Ko
Journal:  Life (Basel)       Date:  2022-01-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.